HAE · Haemonetics Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $1.33B | $1.36B | $993.20M | - | - | - |
| Cost of Revenue | $546.44M | $611.87M | $617.51M | $553.56M | $487.69M | $472.63M |
| Gross Profit | $787.59M | $748.96M | $691.55M | $615.10M | $505.50M | $397.84M |
| R&D | $59.77M | $62.72M | $54.44M | $50.13M | $46.80M | $32.86M |
| SG&A | $442.42M | $436.79M | $431.78M | $376.68M | $339.56M | $274.19M |
| Total Operating Expenses | $630.85M | $527.14M | $526.66M | $459.06M | $424.75M | $308.09M |
| D&A | $111.72M | $115.59M | $97.22M | $93.31M | $97.75M | $84.29M |
| Operating Income | $156.73M | $221.82M | $164.88M | $156.03M | $80.75M | $89.75M |
| Interest Expense | $19.30M | $35.90M | $19.50M | $13.00M | $5.80M | $9.40M |
| Income Tax | $30.72M | $44.39M | $34.31M | $26.00M | $20.25M | ($6.56M) |
| Net Income | $97.31M | $167.68M | $117.56M | $115.40M | $43.38M | $79.47M |
| EPS - Basic | $2.06 | $3.33 | $2.32 | $2.27 | $0.85 | $1.57 |
| EPS - Diluted | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 |
Balance Sheet
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $245.44M | $306.76M | $178.80M | $284.47M | $259.50M | $192.31M |
| Accounts Receivable | $216.85M | $202.66M | $206.56M | $179.14M | $159.38M | $127.56M |
| Inventory | $306.37M | $365.14M | $317.20M | $259.38M | $293.03M | $322.61M |
| Accounts Payable | $51.06M | $67.00M | $73.36M | $63.93M | $58.37M | $50.29M |
| Current Assets | $834.88M | $934.98M | $768.90M | $769.72M | $756.03M | $693.55M |
| Total Assets | $2.40B | $2.45B | $2.20B | $1.93B | $1.86B | $1.82B |
| Current Liabilities | $282.60M | $578.11M | $300.38M | $251.82M | $442.27M | $253.50M |
| Long-term Debt | $1.22B | $921.23M | $797.56M | $754.10M | $559.44M | $690.59M |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $796.32M | $820.84M | $959.96M | $818.00M | $749.42M | $731.67M |
| Retained Earnings | $279.34M | $352.17M | $360.46M | $253.17M | $202.39M | $157.98M |
Cash Flow
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $293.22M | $181.72M | $181.75M | $273.06M | $172.26M | $108.81M |
| Investing Cash Flow | ($179.55M) | ($161.90M) | ($322.39M) | ($143.79M) | ($86.34M) | ($425.44M) |
| Financing Cash Flow | ($178.46M) | $108.82M | $38.16M | ($100.36M) | ($15.75M) | $367.45M |
| CapEx | $32.78M | $39.28M | $66.30M | $110.19M | $96.51M | $37.04M |
| Free Cash Flow | $260.44M | $142.45M | $115.45M | $162.87M | $75.75M | $71.77M |
Ratios
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 59.0% | 55.0% | 69.6% | - | - | - |
| Operating margin | 11.7% | 16.3% | 16.6% | - | - | - |
| EBITDA margin | 20.1% | 24.8% | 26.4% | - | - | - |
| Net margin | 7.3% | 12.3% | 11.8% | - | - | - |
| Free cash flow margin | 19.5% | 10.5% | 11.6% | - | - | - |
| FCF / Net income | 2.68 | 0.85 | 0.98 | 1.41 | 1.75 | 0.90 |
| R&D / Revenue | 4.5% | 4.6% | 5.5% | - | - | - |
| SG&A / Revenue | 33.2% | 32.1% | 43.5% | - | - | - |
| Effective tax rate | 24.0% | 20.9% | 22.6% | 18.4% | 31.8% | -9.0% |
| Return on assets | 4.1% | 6.8% | 5.4% | 6.0% | 2.3% | 4.4% |
| Return on equity | 12.2% | 20.4% | 12.2% | 14.1% | 5.8% | 10.9% |
| Return on invested capital | 5.9% | 10.1% | 7.3% | 8.1% | 4.2% | 6.3% |
| Liquidity | ||||||
| Current ratio | 2.95 | 1.62 | 2.56 | 3.06 | 1.71 | 2.74 |
| Quick ratio | 1.87 | 0.99 | 1.50 | 2.03 | 1.05 | 1.46 |
| Cash ratio | 0.87 | 0.53 | 0.60 | 1.13 | 0.59 | 0.76 |
| Leverage | ||||||
| Debt / Equity | 1.53 | 1.12 | 0.83 | 0.92 | 0.75 | 0.94 |
| Debt / Assets | 0.51 | 0.38 | 0.36 | 0.39 | 0.30 | 0.38 |
| Debt / EBITDA | 4.54 | 2.73 | 3.04 | 3.02 | 3.13 | 3.97 |
| Interest coverage | 8.1x | 6.2x | 8.5x | 12.0x | 13.9x | 9.5x |
| Equity multiplier | 3.01 | 2.99 | 2.29 | 2.37 | 2.48 | 2.49 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.56 | 0.56 | 0.45 | - | - | - |
| Inventory turnover | 1.78 | 1.68 | 1.95 | 2.13 | 1.66 | 1.46 |
| Days sales outstanding | 59d | 54d | 76d | - | - | - |
| Days inventory outstanding | 205d | 218d | 187d | 171d | 219d | 249d |
| Days payable outstanding | 34d | 40d | 43d | 42d | 44d | 39d |
| Cash conversion cycle | 230d | 232d | 220d | - | - | - |
| Valuation | ||||||
| P / E | 26.4x | 19.2x | 37.3x | 36.9x | 76.0x | 72.3x |
| P / B | 3.2x | 3.9x | 4.6x | 5.2x | 4.4x | 7.9x |
| P / S | 1.9x | 2.4x | 4.4x | - | - | - |
| EV / EBITDA | 13.2x | 11.4x | 19.1x | 18.9x | 20.0x | 35.9x |
| Growth | ||||||
| Revenue growth (YoY) | -2.0% | 37.0% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | 5.2% | 8.3% | 12.4% | 21.7% | 27.1% | -17.9% |
| Operating income growth (YoY) | -29.3% | 34.5% | 5.7% | 93.2% | -10.0% | -13.2% |
| Net income growth (YoY) | -42.0% | 42.6% | 1.9% | 166.1% | -45.4% | 3.8% |
| EPS growth (YoY) | -38.1% | 44.5% | 2.2% | 166.7% | -45.8% | 4.7% |
| EPS CAGR (3y) | -2.9% | 57.9% | 13.9% | 14.8% | -6.9% | 22.2% |
| EPS CAGR (5y) | 5.8% | 17.5% | 17.1% | 21.4% | - | - |
| FCF growth (YoY) | 82.8% | 23.4% | -29.1% | 115.0% | 5.6% | -34.4% |
| FCF CAGR (5y) | 29.4% | 5.4% | 23.4% | 2.3% | -2.0% | 29.8% |
| Book value growth (YoY) | -3.0% | -14.5% | 17.4% | 9.2% | 2.4% | 24.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-03-28.
Product / service
$979.32M totalPlasma Productsand Services$524.46M · 53.6%
Hospital Productsand Services$234.01M · 23.9%
Blood Center Productsand Services$220.86M · 22.6%
Stability scores
Piotroski F-score
FY 2026 · 9-point quality
7/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing HAEMONETICS CORP against the 5 most active filers in the same SIC group.